<DOC>
	<DOCNO>NCT01851746</DOCNO>
	<brief_summary>The purpose study evaluate effectiveness security lobaplatin combine docetaxel treatment sensitive recurrent ovarian cancer .</brief_summary>
	<brief_title>A Study Docetaxel Lobaplatin Versus Docetaxel Carboplatin Combination Regimen Patients With Platinum-sensitive ( &gt; 6 Months ) Relapsed Ovarian Cancer</brief_title>
	<detailed_description />
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>1. age 18 70 year old 2. sing information consent form 3 . Expected survival time &gt; 3 month 4 . Recurrence least 6 month receive initial platinumbased chemotherapy without cytoreductive surgery indication . 1 . Recurrence within 6 month receive initial platinumbased chemotherapy 2. without radiographic evidence tumor recurrence 3. receiving chemotherapy , hormone therapy , immunotherapy , radiation therapy</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>May 2013</verification_date>
	<keyword>recurrent ovarian cancer</keyword>
	<keyword>lobaplatin</keyword>
	<keyword>docetaxel</keyword>
	<keyword>carboplatin</keyword>
</DOC>